Rupa Redding‐Lallinger
About
In The Last Decade
Rupa Redding‐Lallinger
25 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 75
- Genetics 822
- Hematology 680
- Pediatrics, Perinatology and Child Health 295
- Molecular Biology 90
- Physiology 69
Countries citing papers authored by Rupa Redding‐Lallinger
This map shows the geographic impact of Rupa Redding‐Lallinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rupa Redding‐Lallinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rupa Redding‐Lallinger more than expected).
Fields of papers citing papers by Rupa Redding‐Lallinger
This network shows the impact of papers produced by Rupa Redding‐Lallinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rupa Redding‐Lallinger. The network helps show where Rupa Redding‐Lallinger may publish in the future.
Co-authorship network of co-authors of Rupa Redding‐Lallinger
This figure shows the co-authorship network connecting the top 25 collaborators of Rupa Redding‐Lallinger. A scholar is included among the top collaborators of Rupa Redding‐Lallinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rupa Redding‐Lallinger. Rupa Redding‐Lallinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 5 | |
| 3 | CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Safety of Hydroxyurea in Children With Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial | 1 |
| 4 | 20 | |
| 5 | 8 | |
| 6 | 21 | |
| 7 | 6 | |
| 8 | 45 | |
| 9 | 50 | |
| 10 | 30 | |
| 11 | 59 | |
| 12 | 23 | |
| 13 | 37 | |
| 14 | 83 | |
| 15 | 9 | |
| 16 | Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. | 349 |
| 17 | 57 | |
| 18 | 11 | |
| 19 | 38 | |
| 20 | 49 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.